Iterum Therapeutics(ITRM) - 2023 Q4 - Annual Results

EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results --Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections cau ...